Abstract
(1) Background: In drug discovery and pharmaceutical quality control, a challenge is to assess protein extracts used for allergy therapy and in vivo diagnosis, such as prick tests. Indeed, there are significant differences between the features of marketed products due to variations in raw materials, purification processes, and formulation techniques. (2) Methods: A protein array technology has been developed to provide comprehensive information on protein-biomarker interactions on a large scale to support the pharmaceutical industry and clinical research. The biosensing method is based on immobilizing low volumes of protein extracts (40 nL) on thermoplastic chips in array format. The biological activity was estimated by incubating with serum from representative food allergy patients. (3) Results: The reproducible optical signals were registered (deviation lower than 10%) using low-cost technologies such as a smartphone and a reader of digital versatile discs. The method was applied to pharmaceutical products to diagnose ten common food allergies, including barley, kiwi, milk, prawn, egg, peanut, wheat, peach, walnut, and squid. Quality indicators were established from spot intensities, enabling an effective comparison of manufacturers. (4) Conclusions: A biosensing-based strategy for screening pharmaceutical products emerges as a reliable and advantageous alternative to traditional approaches such as electrophoresis, fluorescence chips, and ELISA assays. This high-throughput method can contribute to understanding complex biological processes and evaluate the performance of pharmaceutical products.